Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, 2-1-50, Minamikoshigaya, Koshigaya-Shi, Saitama, 343-8555, Japan.
Department of Hematology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8602, Japan.
Int J Hematol. 2023 May;117(5):631-633. doi: 10.1007/s12185-023-03578-y. Epub 2023 Mar 25.
Cancer immunotherapies including immune checkpoint inhibitor and cell-based regimens such as chimeric antigen receptor T cell therapy have progressed markedly in the last decade. However, the efficacy of those cancer immunotherapies is still limited in some patient populations due to the many mechanisms of antitumor immunomodulation, including immune checkpoint molecules expressed by both tumor cells and the tumor microenvironment, immunosuppressive cells, and tumor cell-derived factors such as extracellular vesicles. In this PIH review series, we focus on new knowledge and strategies to improve immunotherapies for cancer patients.
在过去的十年中，癌症免疫疗法，包括免疫检查点抑制剂和基于细胞的疗法，如嵌合抗原受体 T 细胞疗法，已经取得了显著进展。然而，由于抗肿瘤免疫调节的许多机制，包括肿瘤细胞和肿瘤微环境表达的免疫检查点分子、免疫抑制细胞以及肿瘤细胞衍生的因子如细胞外囊泡，这些癌症免疫疗法在一些患者群体中的疗效仍然有限。在本 PIH 综述系列中，我们重点介绍了提高癌症患者免疫疗法的新知识和策略。
